ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Pre-Administration of Akkermansia Muciniphila Prevents the Development of Severe Acute Graft-Versus-Host Disease in Systemic Organs.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Overconsumption of fructose aggravates acute GVHD by inducing gut dysbiosis and promoting macrophage-mediated inflammatory response.Gut microbes · 2026Article
- The Role of the Gut Microbiota in Allogeneic Hematopoietic Cell Transplantation.American journal of hematology · 2026Review
- Pre-Administration of Akkermansia Muciniphila Prevents the Development of Severe Acute Graft-Versus-Host Disease in Systemic Organs.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Acute graft-versus-host disease (aGvHD) remains a significant clinical challenge, with no optimal treatment despite advancements in medical science. This life-threatening condition, characterized by multi-organ involvement and high mortality, is increasingly linked to the gut microbiota. Therefore, this study investigates the protective effects of Akkermansia muciniphila on aGvHD, focusing on its capacity to modulate the gut microbiome and reduce disease symptoms. A. muciniphila is orally administered to mice prior to inducing aGvHD through allogeneic hematopoietic stem cell transplantation. The effects of A. muciniphila administration on the development of aGvHD are assessed through disease activity scoring, histological analysis, metabolite and immune profiling, and gut microbiota analyses. Pre-administration of A. muciniphila significantly reduces aGvHD severity, particularly in the gastrointestinal tract, alleviates gut dysbiosis, and increases the levels of metabolites such as tauroursodeoxycholic acid and short-chain fatty acids. These findings provide the basis for new therapeutic strategies for aGvHD and contribute to improving treatment outcomes for patients with intractable diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.